Imperial College Hammersmith Campus
London, W12 0NN, United Kingdom
NCT Number: NCT00230659
We will address coagulation parameters in hereditary haemorrhagic telangiectasia (HHT) compared to controls.
Looking for future studies?
Notify MeAll sexes
Observational
London, W12 0NN, United Kingdom
The inherited disease hereditary haemorrhagic telangiectasia (HHT) causes bleeding from dilated fragile vessels, particularly in the nose and gut. However, many HHT patients develop deep venous thromboses and/or pulmonary embolism, necessitating treatments with anticoagulants that further impair control of their haemorrhagic state. Our initial observations using general coagulation tests suggest that the blood of HHT patients is intrinsically hypercoagulable.
We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of one or several of the proteins which affect blood clotting leading to a hypercoagulable state.
We propose to study levels and activity of blood coagulation factors in people with hereditary haemorrhagic telangiectasia and in normal volunteers. This should define the significance and basis for our initial observations, and will have significant implications for the clinical management of HHT patients.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blood sample to be taken.
Imperial College London
Other
Investigation of Coagulation Parameters in Hereditary Haemorrhagic
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02157987
Cardiovascular Abnormalities, Cardiovascular Diseases
Caen, France
View Trial DetailsNCT04108052
Arteriovenous Malformations, Cardiovascular Abnormalities
Bron, France
View Trial DetailsNCT02484716
Cardiovascular Abnormalities, Cardiovascular Diseases
Bron, France
View Trial DetailsNCT03227263
Cardiovascular Abnormalities, Cardiovascular Diseases
Angers, France
View Trial Details